Plavix and Abilify lift BMS's sales
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb reported an increase in revenue as sales of its anticoagulant Plavix (clopidogrel bisulfate) and its antipsychotic treatment Abilify (aripiprazole) rallied in the third quarter. Net sales grew by 4% to $5.5 billion but profits slipped from the year-earlier period, when BMS booked an almost $2 billion gain from the disposal of its ConvaTec business.